[ad_1]
Mainz-based company Biontech and its partner Pfizer want to deliver 12.5 million doses of Covid 19 vaccination in the EU alone by the end of the year. Biontech boss Sahin calmly sees Britain’s new variant of the virus.
From a scientific point of view, according to the head of Biontech, Ugur Sahin, it is very likely that the Covid-19 vaccine from Biontech and Pfizer will also work against the mutated variant discovered in Britain.
Ugur Sahin, head and co-founder of Mainz biotech company Biontech, is confident that the Covid 19 vaccine developed by his company together with the US company Pfizer will also work against the new mutation of the virus that is widespread in Britain. From a scientific point of view, the likelihood of this happening is very high, he said Tuesday morning at an online news conference. The vaccine has already been tested to determine its effectiveness against other mutations and the immune response has always been very similar. The variant of the virus in Great Britain, however, involves nine individual mutations, not just one.
